Clinical trials
Positron Emission Tomography clinical trials
Below are recruiting positron emission tomography clinical trials, each written for real people, not researchers. We’re tracking 356 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06894745RecruitingPhase 1
PET imaging of solid tumors with 89Zr-DFO-starPEG
This early-phase trial tests a new imaging agent called 89Zr-DFO-starPEG that may help doctors see solid tumors more clearly on PET scans. It is a safety and imaging study, not a treatment, and may help find tumors in people with various types of cancer.
San Francisco, CaliforniaAges 18 years+ - NCT05873777Recruiting
PET/CT scans to compare two tracers in FAP or SSTR2-positive cancer
This study compares two special PET/CT scan tracers—68Ga-FAPI-LM3 and 18F-FDG—to see how well they detect cancer that shows FAP or SSTR2 signals. It may help doctors choose better imaging to find or assess certain tumors.
Xiamen, FujianAges 18 years+ - NCT05656105RecruitingEarly Phase 1
PET scan study of brain inflammation after COVID
This early-phase study uses a special PET scan to look for signs of brain inflammation in people with ongoing (long-term) nervous system symptoms after COVID-19. It may help researchers understand what is driving symptoms and whether this imaging approach can detect inflammation.
Birmingham, AlabamaAges 18–65 - NCT04983095Recruiting
Targeted radiation for a few prostate cancer metastases
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
Lund, LundAges 18 years+ - NCT06387381RecruitingEarly Phase 1
PET scan for PSMA/FAP-positive cancer
This trial tests a special PET scan using a tracer that attaches to certain markers (PSMA and FAP) found on some cancers. It aims to help doctors see where the cancer is, possibly leading to better treatment decisions.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06355713Recruiting
Symptom improvement after Essure implant removal
This study looks at women who are having symptoms from their Essure contraceptive implant and want it removed. It will measure how their symptoms improve after removal and may also include a special brain scan (MRI-PET) to check for changes.
AngersAges 35–75 - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT07087964Recruiting
PET scans to better understand multiple myeloma risk and disease
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
Antwerp, AntwerpenAges 18 years+ - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT05188872Recruiting
PET scan for adrenal hormone condition before and after treatment
This trial uses a special PET scan to look at a hormone gland condition called primary aldosteronism, which can cause high blood pressure. It aims to see if the scan helps doctors plan treatment and check results.
Fuzhou, FujianAges 19–90 - NCT06609928RecruitingPhase 1
CAR T cell therapy for children with relapsed AML that has FOLR1
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
Seattle, WashingtonAges Up to 6 years - NCT06373497RecruitingEarly Phase 1
Heart artery health after chest radiation using PET scan
This study looks at how radiation therapy to the chest affects the arteries in your heart. It uses a special PET scan (with a safe radioactive tracer) to check for early signs of inflammation or plaque buildup, which can help doctors find ways to protect your heart during cancer treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07618936Recruiting
PD-L1 PET/CT imaging scan for cancer patients
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
Hefei, AnhuiAges 18–80 - NCT07083011RecruitingPhase 2
PET scan study for heart failure and cardiac sarcoidosis
This study uses a special PET scan (68Ga-FAPI) to look at inflammation in the heart. It may help researchers understand heart failure and cardiac sarcoidosis better.
Rochester, MinnesotaAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Birmingham, AlabamaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Birmingham, AlabamaAges Any age - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT07593976RecruitingPhase 2
New PET scan to predict breast cancer treatment response
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
RouenAges 18 years+ - NCT04499365RecruitingEarly Phase 1
PET scan for detecting different cancer types
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
Fuzhou, FujianAges 18–90 - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
Los Angeles, CaliforniaAges 18 years+ - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT03457493RecruitingPhase 1/Phase 2
TSPO brain scan study in Parkinson’s disease
This trial looks at brain inflammation in people with Parkinson’s using a special PET scan. The goal is to understand how brain immune activity may relate to Parkinson’s, and how the scan results change over time.
Birmingham, AlabamaAges 30 years+ - NCT03716401Recruiting
Imaging tests to predict kidney disease in type 2 diabetes
This study uses special kidney imaging to look for patterns that can predict how diabetic kidney disease may progress. It may help researchers find better ways to identify people at higher risk using noninvasive (and possibly biopsy-related) tests.
TurkuAges 18–80 - NCT03830320RecruitingPhase 1
PET scan to look for blood clots in the heart or lungs
This Phase 1 study uses a PET scan to detect blood clots (thrombosis) in specific groups of people. It’s testing how well the scan can find clots and how it should be timed with other heart or illness tests.
Boston, MassachusettsAges 18–85
Hear when a new Positron Emission Tomography trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for positron emission tomography?
- Yes. Clin2 currently lists 356 recruiting positron emission tomography studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a positron emission tomography trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a positron emission tomography trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.